- Home
- JRS vs TNXP Comparison
JRS vs TNXP Comparison
Compare JRS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- TNXP
- Stock Information
- Founded
- JRS 2001
- TNXP 2007
- Country
- JRS United States
- TNXP United States
- Employees
- JRS N/A
- TNXP N/A
- Industry
- JRS Finance/Investors Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- TNXP Health Care
- Exchange
- JRS Nasdaq
- TNXP Nasdaq
- Market Cap
- JRS 231.7M
- TNXP 213.7M
- IPO Year
- JRS N/A
- TNXP N/A
- Fundamental
- Price
- JRS $8.07
- TNXP $17.59
- Analyst Decision
- JRS
- TNXP Buy
- Analyst Count
- JRS 0
- TNXP 1
- Target Price
- JRS N/A
- TNXP $70.00
- AVG Volume (30 Days)
- JRS 86.6K
- TNXP 661.7K
- Earning Date
- JRS 01-01-0001
- TNXP 11-10-2025
- Dividend Yield
- JRS 8.87%
- TNXP N/A
- EPS Growth
- JRS N/A
- TNXP N/A
- EPS
- JRS N/A
- TNXP N/A
- Revenue
- JRS N/A
- TNXP $10,299,000.00
- Revenue This Year
- JRS N/A
- TNXP $14.79
- Revenue Next Year
- JRS N/A
- TNXP $933.49
- P/E Ratio
- JRS N/A
- TNXP N/A
- Revenue Growth
- JRS N/A
- TNXP N/A
- 52 Week Low
- JRS $5.95
- TNXP $6.76
- 52 Week High
- JRS $8.00
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- JRS 52.09
- TNXP 35.76
- Support Level
- JRS $7.85
- TNXP $16.10
- Resistance Level
- JRS $8.12
- TNXP $18.96
- Average True Range (ATR)
- JRS 0.09
- TNXP 1.02
- MACD
- JRS 0.00
- TNXP 0.31
- Stochastic Oscillator
- JRS 55.56
- TNXP 32.81
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.